Macrogenics Inc Stock Price, News & Analysis

MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its fourth quarter 2022 financial results on March 15, 2023, after market close. A conference call to discuss these results and corporate progress will follow at 4:30 pm ET on the same day. Investors can register in advance for telephone participation, receiving a confirmation email with access details. A listen-only webcast will also be available on the company's website under the Investor Relations section. MacroGenics is focused on developing innovative monoclonal antibody therapeutics for cancer treatment, leveraging proprietary antibody technology and strategic collaborations.

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in significant investor conferences in March 2023. The company's President & CEO, Scott Koenig, will join the TD Cowen’s 43rd Annual Health Care Conference in Boston on March 7, 2023, for a corporate panel discussion. Additionally, he will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami on March 14, 2023. Management will also engage in one-on-one meetings during both events. Webcasts of the presentations will be available on the company's Investor Relations website, with an archived replay for 30 days.

MacroGenics announced preliminary results from the Phase 1 trial of lorigerlimab for metastatic castration-resistant prostate cancer (mCRPC). In the cohort expansion, 12 of 42 patients achieved ≥ 50% reduction in PSA levels, while 9 patients (21.4%) had ≥ 90% reduction. The overall safety profile was manageable, with the company preparing to launch a Phase 2 study in mCRPC later in 2023. These findings are set to be presented at the ASCO-GU Symposium, showcasing the therapeutic potential of lorigerlimab and indicating promising efficacy in mCRPC patients.

ROCKVILLE, MD, Feb. 6, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on antibody-based therapeutics for cancer, has announced participation in two investor conferences. On February 9, 2023, President & CEO Scott Koenig, M.D., Ph.D., will engage in a fireside chat at the Guggenheim Healthcare Talks in New York. Following this, on February 14, 2023, he will present at the SVB Securities Global Biopharma Conference. Both events will also include one-on-one meetings. Interested parties can access a webcast of these presentations on the MacroGenics Investor Relations website, available for 30 days.

MacroGenics, a biopharmaceutical company focused on innovative antibody-based cancer therapies, will present at the 41^st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President & CEO, will deliver a business update on January 12, 2023, at 9:45 am PT / 12:45 pm ET. The presentation can be accessed via a webcast on MacroGenics' Investor Relations webpage, with an archived replay available for 30 days. MacroGenics leverages proprietary antibody technology platforms to develop its pipeline and establish strategic collaborations.

MacroGenics, Inc. (NASDAQ: MGNX) announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu, a renowned expert in gene therapy and immunotherapy, will join the Science and Technology Committee, while Ms. Karson will serve on the Audit Committee. The Board now consists of ten directors, nine of whom are independent, emphasizing strengthened leadership. Both appointees bring extensive experience from their previous roles in biopharmaceuticals, enhancing the company’s strategic capabilities in cancer therapeutics.

MacroGenics, Inc. (NASDAQ: MGNX) announced that the U.S. FDA has approved the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody, previously developed by the company. Acquired by Provention Bio in 2018, teplizumab represents a significant advancement for individuals with type 1 diabetes. Provention will pay MacroGenics up to $395 million in milestone payments, including $60 million for the BLA approval. MacroGenics expects to maintain a cash runway into late 2024, based on current cash and anticipated partnership payments.

MacroGenics, Inc. (NASDAQ: MGNX) announced significant corporate progress, including a $60 million collaboration with Gilead for the development of bispecific antibodies such as MGD024. The company reported a net loss of $24.8 million for Q3 2022, an improvement from $52.9 million in Q3 2021. Revenue increased to $41.7 million, boosted by milestone payments and product sales. MacroGenics anticipates initiating the Phase 2 TAMARACK prostate cancer study by year-end 2022 and expects cash runway to extend into mid-2024, supported by recent financial influxes.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on cancer therapeutics, will participate in several investor conferences throughout November 2022. Key events include a BMO Biopharma Spotlight Series fireside chat on November 9 at 2:30 pm ET, a Stifel Healthcare Conference chat on November 15 at 10:55 am ET, and an Evercore ISI HEALTHCONx Conference chat on November 30 at 8:50 am ET. Management will also hold one-on-one meetings at these events. Webcasts will be available on the MacroGenics website.